



Company Overview

Heat Biologics a biopharmaceutical company that develops immunotherapies with the goal of activating a patient's immune system against cancer through T-cell activation. Our proprietary, T-cell Activation Platform (TCAP) produces therapies designed to turn "cold" tumors "hot," and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase effectiveness. We are currently enrolling patients in our Phase 2 clinical trial for non-small cell lung cancer, in combination with Bristol-Myers Squibb's nivolumab (Opdivo®). We also have numerous pre-clinical programs at various stages of development.

Heat Biologics to Present at the Chinese Society for Clinical Oncology Conference on Immunotherapy

Mar 21 2019, 7:00 AM EDT

Heat Biologics Lead Director to Chair Oncology Roundtable Discussion at WuXi Healthcare Forum in Shanghai

Mar 5 2019, 9:25 AM EST

Heat Biologics Presents Interim Phase 2 Lung Cancer Data on HS-110 + Nivolumab at ASCO-SITC Clinical Immuno-Oncology Symposium

Feb 28 2019, 5:00 PM EST

Stock Overview

Symbol	HTBX
Exchange	Nasdaq
Market Cap	40.25m
Last Price	\$1.24
52-Week	\$0.952 - \$4.30

03/26/2019 03:59 PM EDT

Investor Relations

investorrelations@heatbio.com

Management Team

Jeffrey Wolf

Founder, Chairman and CEO

Jeff Hutchins, Ph.D.

Chief Scientific and Operating Officer

George Peoples, M.D., FACS

Chief Medical Advisor

Ann A. Rosar, M.B.A.

Vice President of Finance

Lori McDermott, RN, BSN, MS, PMP

Vice President, Clinical Development

Janice Marie McCourt, R.P.h, M.B.A.

Vice President, Business Development

Gary Vinson

Vice President, Chemistry and Manufacturing Controls (CMC)

Heat Biologics, Inc.

801 Capitola Drive
Suite 12
Durham, NC 27713

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and it's quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.